Synthesis and anticancer activities of 3-arylflavone-8-acetic acid derivatives

被引:25
作者
Yan, Guang-Hua [1 ]
Li, Xiao-Fang [2 ]
Ge, Bing-Chen [1 ]
Shi, Xiu-Dong [1 ]
Chen, Yu-Fang [1 ]
Yang, Xue-Mei [1 ]
Xu, Jiang-Ping [1 ]
Liu, Shu-Wen [1 ]
Zhao, Pei-Liang [1 ]
Zhou, Zhong-Zhen [1 ]
Zhou, Chun-Qiong [1 ]
Chen, Wen-Hua [1 ]
机构
[1] Southern Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Guangdong, Peoples R China
[2] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou 510515, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
3-Arylflavone-8-acetic acid; Direct cytotoxicity; Indirect cytotoxicity; Tumor necrosis factor alpha; ANTIVASCULAR AGENT DMXAA; TUMOR-NECROSIS-FACTOR; 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID; ASA404; VADIMEZAN; PHASE-II; IN-VITRO; CELLS; INHIBITION; FLAVONOIDS; INDUCTION;
D O I
10.1016/j.ejmech.2014.11.030
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This paper describes the synthesis and the antiproliferative activities of compounds 9a-r, 3-aryl analogs of flavone-8-acetic acid that bear diverse substituents on the benzene rings at the 2- and 3-positions of the flavone nucleus. Their direct and indirect cytotoxicities were evaluated against HT-29 human colon adenocarcinoma cell lines, A549 lung adenocarcinoma cell lines and Human Peripheral Blood Mononuclear Cells (HPBMCs). The results indicate that most of the compounds bearing electron-withdrawing substituents (9b-m) exhibited moderate direct cytotoxicities. And compounds 9e and 9i showed comparable indirect cytotoxicities with 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), and low direct cytotoxicities toward HPBMCs. Interestingly, the compounds 9n-r bearing methoxy groups at the 2- or 3-position of the flavone nucleus exhibited higher indirect cytotoxicities against A549 cell lines than DMXAA, and lower cytotoxicities against HPBMCs. In addition, compounds 9p-r were found to be able to induce tumor necrosis factor alpha (TNF-alpha) production in HPBMCs. (C) 2014 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:251 / 257
页数:7
相关论文
共 33 条
[1]  
ATASSI G, 1985, EUR J MED CHEM, V20, P393
[2]  
Babu BV, 2013, ANTI-CANCER AGENT ME, V13, P307
[3]  
Baguley B. C., 2012, Clinical Investigation, V2, P985
[4]   Immunomodulatory actions of xanthenone anticancer agents [J].
Baguley, BC ;
Ching, LM .
BIODRUGS, 1997, 8 (02) :119-127
[5]   Antivascular therapy of cancer: DMXAA [J].
Baguley, BC .
LANCET ONCOLOGY, 2003, 4 (03) :141-148
[6]   Temporal aspects of the action of ASA404 (vadimezan; DMXAA) [J].
Baguley, Bruce C. ;
Siemann, Dietmar W. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (11) :1413-1425
[7]  
Cao ZH, 2001, CANCER RES, V61, P1517
[8]  
Chahar Maheep K, 2011, Pharmacogn Rev, V5, P1, DOI 10.4103/0973-7847.79093
[9]  
CHING LM, 1994, CANCER RES, V54, P870
[10]   Relationship between tumour enclothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice [J].
Ching, LM ;
Zwain, S ;
Baguley, CC .
BRITISH JOURNAL OF CANCER, 2004, 90 (04) :906-910